NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









GRO Biosciences

GRO Biosciences

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://grobio.com/

Last Round

Series B

Jul 19, 2024

Est. Valuation

$90.3M

Total Funding Raised

$88.4M

Company Overview

GRO Biosciences is a biotechnology company that develops enhanced protein therapeutics using genomically recoded organisms to create biologics with non-standard amino acids for improved potency, stability, and targeted delivery.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

synthetic biologygenomically recoded organismGROprotein therapeuticsnon-standard amino acidsNSAAprotein engineeringdrug discoverybiotech startupgenetic code expansionbiopharmatherapeutic developmentGeorge Church lab

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GRO Biosciences Comparables

Compare GRO Biosciences with similar companies based on industry and business-model similarity.

GRO Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Pearl Bio
87%
BrickBio, Inc.
84%
Tektonyx Bio, Inc.
82%

GRO Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJul 19, 2024
Series ANov 3, 2021
GrantSep 15, 2020
SeedSep 28, 2017

Key People

Founding team and executive leadership

Nicole K. Paulk

CEO, Founder, President

Founding Team

GRO Biosciences Investors

Notable investors and investment history

GRO Biosciences investors
InvestorRounds
Redmile GroupSeries B, Series A
Access IndustriesSeries B
Digitalis VenturesSeed, Series A, Series B
Innovation EndeavorsSeries A, Seed, Series B
Atlas VentureSeries B
Leaps by BayerSeries B, Series A
Access BiotechnologySeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 3, 2021

    $25M round led by Leaps by Bayer and Redmile Group.

  • Sep 15, 2020

    $1M grant awarded by the National Science Foundation.

GRO Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

GRO Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about GRO Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range1
Year Founded2016
Last FundingJul 19, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.